Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-marketing Observational Study to Evaluate the Effect of HUMIRA (Adalimumab) Treatment With AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary in a Real-life Setting: VALUE

NCT02750800 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02750800
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02750800 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-marketing Observational Study to Evaluate the Effect of HUMIRA (Adalimumab) Treatment With AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary in a Real-life Setting: VALUE
Lead sponsor
AbbVie
Phase
Observational
Overall status
Completed
Start date
April 7, 2016
Completion date
April 3, 2018
Enrollment
427 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ankylosing spondylitis, crohn's disease, psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis